2012
Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort
LYKKE JA, BARE LA, OLSEN J, LAGIER R, ARELLANO AR, TONG C, PAIDAS MJ, LANGHOFF‐ROOS J. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. Journal Of Thrombosis And Haemostasis 2012, 10: 1320-1325. PMID: 22578003, DOI: 10.1111/j.1538-7836.2012.04773.x.Peer-Reviewed Original ResearchConceptsMethylenetetrahydrofolate reductase (MTHFR) C677TFetal growth restrictionProthrombin mutation G20210APlacental abruptionSevere preeclampsiaGrowth restrictionAllelic modelAdverse pregnancy outcomesBody mass indexCase-cohort studyReductase C677TPreterm deliveryComposite outcomePregnancy outcomesMass indexPregnant womenMedical recordsC677TFV LeidenStudy designSocioeconomic statusPreeclampsiaAbruptionRandom controlsOutcomes
2007
Do Thrombophilias Cause Placenta-Mediated Pregnancy Complications?
Rodger M, Paidas M. Do Thrombophilias Cause Placenta-Mediated Pregnancy Complications? Seminars In Thrombosis And Hemostasis 2007, 33: 597-603. PMID: 17768692, DOI: 10.1055/s-2007-985756.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousFemaleHumansPlacenta DiseasesPregnancyPregnancy ComplicationsRecurrenceThrombophiliaConceptsPlacenta-mediated pregnancy complicationsPregnancy complicationsAnticoagulant prophylaxisIntrauterine growth restrictionThrombophilic pregnanciesNeonatal morbidityPlacental abruptionVenous thromboembolismThrombophilic womenPregnancy lossGrowth restrictionClinical consequencesHigh riskThrombophiliaComplicationsCausal associationProphylaxisAssociationThromboembolismAbruptionPreeclampsiaMorbidityEvidencePregnancyNew associations
2005
Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications
PAIDAS MJ, KU D, LEE M, MANISH S, THURSTON A, LOCKWOOD CJ, ARKEL YS. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. Journal Of Thrombosis And Haemostasis 2005, 3: 497-501. PMID: 15748239, DOI: 10.1111/j.1538-7836.2005.01158.x.Peer-Reviewed Original ResearchConceptsAdverse pregnancy outcomesNormal pregnancy outcomeProtein S levelsPZ levelsPregnancy outcomesProtein SSubsequent pregnancy complicationsProtein ZAdditional risk factorsFree PS antigenPregnancy complicationsPregnant controlsThird trimesterPlasma levelsRisk factorsPatientsThrombophiliaPS antigenS levelsWomenSignificant decreasePS levelsOutcomesLow levelsTrimester
2004
Does heparin therapy improve pregnancy outcome in patients with thrombophilias?
Paidas M, Ku D, Triche E, Lockwood C, Arkel Y. Does heparin therapy improve pregnancy outcome in patients with thrombophilias? Journal Of Thrombosis And Haemostasis 2004, 2: 1194-1195. PMID: 15219211, DOI: 10.1111/j.1538-7836.2004.00784.x.Peer-Reviewed Original ResearchPregnant patients with thrombophilia and subsequent adverse pregnancy outcomes have a decreased first trimester response to thrombomodulin in an activated partial thromboplastin time (APTT) system
Paidas M, Ku D, Lee M, Lockwood C, Arkel Y. Pregnant patients with thrombophilia and subsequent adverse pregnancy outcomes have a decreased first trimester response to thrombomodulin in an activated partial thromboplastin time (APTT) system. Journal Of Thrombosis And Haemostasis 2004, 2: 840-841. PMID: 15099295, DOI: 10.1111/j.1538-7836.2004.00680.x.Peer-Reviewed Original Research
2002
The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders
Arkel Y, Paidas M, Ku D. The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagulation & Fibrinolysis 2002, 13: 199-205. PMID: 11943933, DOI: 10.1097/00001721-200204000-00005.Peer-Reviewed Original ResearchMeSH KeywordsActivated Protein C ResistanceAdolescentAdultAgedAged, 80 and overAntiphospholipid SyndromeAntithrombin IIIAntithrombin III DeficiencyAutoimmune DiseasesBiomarkersEnzyme-Linked Immunosorbent AssayFactor VFemaleFibrinFibrin Fibrinogen Degradation ProductsHumansHyperhomocysteinemiaMaleMiddle AgedPeptide FragmentsPeptide HydrolasesProtein C DeficiencyProtein S DeficiencyProthrombinRiskSolubilityThrombophiliaConceptsCoagulation activation markersActivation markersAssessment of hypercoagulabilityPercentage of patientsProthrombotic disordersVascular eventsConsecutive patientsThrombophilic abnormalitiesThrombotic riskPatientsSoluble fibrin polymersTPP levelsMean levelsMarkersAbnormalitiesFibrin polymersHypercoagulability